Home › Peptides A to Z › VasopressinWhat is Vasopressin? A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Vasopressin in the library · · Human Trials · What are peptides?
109 registered trials · 1324 indexed papers · 2394 human / 4329 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Type: Peptide hormone.
Definition (National Library of Medicine) “The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.”
MeSH: Arginine Vasopressin Human research The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Vasopressin is one of its interventions, or is named in the study title or subject headings.
Listing a study does not mean it showed a benefit, and it is not medical advice.
Registered human trials (109) Peer-reviewed studies (1324) Paper Authors Journal Year Type Open-Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period, Three-Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution Christensen A et al. Clinical pharmacology in drug development 2026 Randomized Controlled Trial Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre-Specified Secondary Analysis of the TVFR Trial Warren AM et al. Clinical endocrinology 2026 Randomized Controlled Trial Ginkgo biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis: A randomized controlled trial El-Shazly M et al. Journal of pediatric urology 2026 Randomized Controlled Trial Oxytocin substitution therapy in patients with AVP deficiency (central diabetes insipidus): study protocol of a double-blind, randomised placebo-controlled trial Atila C et al. BMJ open 2026 Clinical Study Copeptin kinetics in healthy aging Lustenberger S et al. The Journal of clinical endocrinology and metabolism 2026 Randomized Controlled Trial Intravenous Tranexamic Acid Combined With Intramyometrial Desmopressin During Laparoscopic Myomectomy: A Randomized Double-Blind Placebo-Controlled Trial Ozbasli E et al. Journal of minimally invasive gynecology 2026 Randomized Controlled Trial Haemostatic effectiveness of intranasal desmopressin for tunnelled dialysis catheter placement: a pilot randomised controlled trial Arshad AR et al. International urology and nephrology 2026 Randomized Controlled Trial Neural signature underlying the effect of intranasal vasopressin on emotional responses to spontaneous social comparison Li X et al. NeuroImage 2026 Randomized Controlled Trial Vasopressin and angiotensin II pathways differentially modulate human fear response dynamics to looming threats Han M et al. PLoS biology 2026 Randomized Controlled Trial Use, efficacy, and safety of desmopressin for congenital nephrogenic diabetes insipidus in children: a nationwide survey Ikegawa K et al. Endocrine journal 2026 Observational Study Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker Hu H et al. Journal of neuroendocrinology 2026 Clinical Trial, Phase II Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls Varaldo E et al. The Journal of clinical endocrinology and metabolism 2026 Randomized Controlled Trial Comparing Vasopressin and Hydrocortisone as Adjunctive Measures in Septic Shock Wang HF et al. The Annals of pharmacotherapy 2026 Observational Study Low Vasopressin in Myalgic Encephalomyelitise/Chronic Fatigue Syndrome Huhmar HM et al. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026 Observational Study Impact of vasopressin initiation at norepinephrine dose thresholds in septic shock patients with high SOFA scores: A retrospective observational cohort study Cortes J et al. Heart & lung : the journal of critical care 2026 Observational Study Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans Galbiati F et al. Journal of neuroendocrinology 2026 Clinical Trial, Phase I Cardiopulmonary effects of vasopressin versus norepinephrine in patients undergoing cardiac surgery: A single-center, cluster-randomized crossover trial Geube M et al. The Journal of thoracic and cardiovascular surgery 2026 Randomized Controlled Trial Vasopressin-induced hyponatremia during mean arterial pressure augmentation in acute spinal cord injury: A multicenter retrospective cohort study Corello H et al. The journal of spinal cord medicine 2026 Observational Study Comparative Efficacy of Desmopressin, Tranexamic Acid, and Phenylephrine in Reducing Bleeding and Improving Surgical Field Quality during Rhinoplasty: A Triple-Blind Randomized Controlled Trial Zamani MR et al. Aesthetic plastic surgery 2026 Randomized Controlled Trial Impact of Desmopressin on Clinical Outcomes in Patients with Spontaneous Antiplatelet-Associated Intracerebral Hemorrhage Undergoing Neurosurgical Intervention: An Observational Multicenter Study Hsu PT et al. Shock (Augusta, Ga.) 2026 Observational Study The Time of the Hypertonic Saline Infusion Test for the Diagnosis of AVP Deficiency Can Be Shortened With LC-MS/MS Handa T et al. The Journal of clinical endocrinology and metabolism 2026 Clinical Trial The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis Hartl L et al. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2026 Observational Study Hyponatremia after pediatric surgery: Randomized trial of fluid composition on antidiuretic hormone response Yokota K et al. Pediatric research 2026 Randomized Controlled Trial Exploring vasopressin use in septic shock: a retrospective cohort study from Türkiye (VASCO-TURK) Küçük AO et al. BMC anesthesiology 2025 Observational Study Role of desmopressin and enuresis alarm in improving sleep quality in children with primary monosymptomatic nocturnal enuresis: A multicentre prospective, randomised study in mainland China Lv L et al. Sleep medicine 2025 Randomized Controlled Trial Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public Databases Sacha GL et al. Critical care explorations 2025 Observational Study Comparative Diagnostic Performance of Copeptin After Hypertonic Saline Infusion Versus Water Deprivation Test in Pediatric Patients with Polyuria-Polydipsia Syndrome Ciortea DA et al. International journal of molecular sciences 2025 Observational Study Parasacral Transcutaneous Electrical Nerve Stimulation with Desmopressin Acetate for Treating Primary Monosymptomatic Enuresis: A Randomized Controlled Clinical Trial Dutra MF et al. International braz j urol : official journal of the Brazilian Society of Urology 2025 Randomized Controlled Trial Efficacy of desmopressin and enuresis alarm in the treatment of monosymptomatic nocturnal enuresis: a multicenter prospective randomized controlled study Zhai R et al. Pediatric nephrology (Berlin, Germany) 2025 Randomized Controlled Trial Prospective Multicenter Observational Study of Patients in Shock Treated with Vasopressin: VASOPRES Registry Study Protocol García Álvarez R et al. Revista espanola de anestesiologia y reanimacion 2025 Clinical Study
More cited research Selective changes in vasopressin neurons and astrocytes in the suprachiasmatic nucleus of Prader-Willi syndrome subjects (2025, human observational)Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures (2025, human observational)Vasopressin Resets the Central Circadian Clock in a Manner Influenced by Sex and Vasoactive Intestinal Polypeptide Signaling (2022, human observational)Loss of arginine vasopressin- and vasoactive intestinal polypeptide-containing neurons and glial cells in the suprachiasmatic nucleus of individuals with type 2 (2019, human observational)GABAergic Signaling from Arginine Vasopressin Neurons in the Suprachiasmatic Nucleus Is Essential for Maintaining the Estrous Cycle in Mice (2026, animal)In vivo recording of suprachiasmatic nucleus dynamics reveals a dominant role of arginine vasopressin neurons in circadian pacesetting (2023, animal)Sex-specific differences in the circadian pattern of action potential firing by rat suprachiasmatic nucleus vasopressin neurons (2023, animal)Female fertility does not require Bmal1 in suprachiasmatic nucleus neurons expressing arginine vasopressin, vasoactive intestinal peptide, or neuromedin-S (2022, animal)Conditions researched Anti-aging & longevity Anxiety and panic Atherosclerosis, cardiovascular disease & high blood pressure Autism support Chronic and systemic inflammation Chronic fatigue syndrome and ME Cognition, focus & brain performance Concussion, traumatic brain injury & stroke recovery Dementia, Alzheimer's & cognitive decline Endometriosis Fat loss, obesity & body recomposition Fatigue & low energy (incl. midlife) Fatty liver & elevated liver enzymes Fight-or-flight and nervous system overdrive Heart repair: after heart attack, heart failure & enlarged heart High cholesterol and statins High-demand jobs: military, fire, police, EMT (and combat-sport athletes) Immune system (general) Insulin resistance, prediabetes & type 2 diabetes Kidney protection (CKD, diabetic kidney, lupus kidney) Low blood pressure and orthostatic hypotension Low testosterone (without or alongside TRT) Lung health, asthma & COPD Lymphedema and swelling Menstrual cramps (dysmenorrhea) Migraine Multiple sclerosis Neuropathy and CRPS Osteoporosis and bone density Parkinson's disease PCOS PMDD (premenstrual dysphoric disorder) Post-surgical inflammation and surgery recovery Pregnancy and breastfeeding: safety notes Prostate inflammation Rheumatoid arthritis Seasonal allergies Skin, hair loss, wounds & mast-cell/histamine reactivity Sleep problems (incl. insomnia on peptides) Tendon, ligament, muscle & joint injuries (incl. athletes) Thick blood and blood clots Related compounds FAQ What is Vasopressin? A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
How many registered human trials study Vasopressin? The PeptideWhiz trial index lists 109 registered trials for Vasopressin, the most recent from 2026.
How much published research exists on Vasopressin? The PeptideWhiz paper index links 1324 PubMed papers to Vasopressin; by study type, 2394 human and 4329 animal studies.
Which conditions is Vasopressin researched for? Anti-aging & longevity, Anxiety and panic, Atherosclerosis, cardiovascular disease & high blood pressure, Autism support, Chronic and systemic inflammation, Chronic fatigue syndrome and ME, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Dementia, Alzheimer's & cognitive decline, Endometriosis, Fat loss, obesity & body recomposition, Fatigue & low energy (incl. midlife), Fatty liver & elevated liver enzymes, Fight-or-flight and nervous system overdrive, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins, High-demand jobs: military, fire, police, EMT (and combat-sport athletes), Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low blood pressure and orthostatic hypotension, Low testosterone (without or alongside TRT), Lung health, asthma & COPD, Lymphedema and swelling, Menstrual cramps (dysmenorrhea), Migraine, Multiple sclerosis, Neuropathy and CRPS, Osteoporosis and bone density, Parkinson's disease, PCOS, PMDD (premenstrual dysphoric disorder), Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Prostate inflammation, Rheumatoid arthritis, Seasonal allergies, Skin, hair loss, wounds & mast-cell/histamine reactivity, Sleep problems (incl. insomnia on peptides), Tendon, ligament, muscle & joint injuries (incl. athletes), Thick blood and blood clots.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).
Reported dosing ranges from research